![]() ![]() In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Zacks' Top Picks to Cash in on Artificial Intelligence If you want an email notification each time Sheraz publishes a new article, please click here> He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. Other noteworthy reports we are featuring today include Boeing (BA), BP p.l.c. (You can read the full research report on Qualcomm here >) Severe competition from major players, huge concentration risks, and softness in demand from China might impair its growth potential. However, high research and development costs are likely to strain its margins. It is on track to record solid revenues across RF front-end, IoT, and Automotive as its business continues to diversify. The Zacks analyst believes that Qualcomm is likely to benefit from solid 5G traction with greater long-term visibility. Qualcomm has already reported solid fourth-quarter fiscal 2021 results with record non-GAAP earnings and revenues, driven by the ramp-up in 5G-enabled chips and a surge in demand for essential products and services that are the building blocks for digital transformation in the cloud economy. Shares of Qualcomm have gained +10.6% in the year to date period against the Zacks Wireless Equipment industry’s gain of +13.7%. (You can read the full research report on Novo Nordisk here >) Sales are also being negatively impacted by COVID-19-related stocking, which is a woe. However, lower realized prices in the United States, loss of exclusivity for products in hormone replacement therapy and intensifying competition will affect sales. Label expansion of these existing drugs will further boost sales. Victoza, Ozempic, Xultophy and Saxenda have been helping the company maintain momentum. Novo Nordisk has one of the broadest diabetes portfolios in the industry. The Zacks analyst believes that Novo Nordisk’s Ozempic is off to a solid start and the launch of Rybelsus also looks impressive. Shares of Novo Nordisk have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+70.1% vs. (You can read the full research report on Adobe here >) However, lower end-market demand and high acquisition expenses remain major overhangs. Further, growth in emerging markets, robust online video creation demand, strong Acrobat adoption and improving average revenue per user remain tailwinds. The company’s Creative Cloud, Document Cloud and Adobe Experience Cloud products are helping it drive top-line growth.Īdditionally, rising subscription revenues and solid momentum across the mobile apps remain major positives. The Zacks analyst believes that Adobe is benefiting from strong demand for its cloud products. Shares of Adobe have gained +31.9% in the year to date period against the Zacks Computer - Software industry’s gain of +42.1%. ![]() You can see all of today’s research reports here > ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |